Gene-regulation map reveals treatment targets for heart failure

Heart failure remains a leading cause of death, yet treatment options remain constrained. Researchers from the University of Utah and UC San Diego have now mapped the genetic regulation of human heart failure with single-cell precision. This research, published in Science, provides a roadmap of cardiac cell types in both healthy and failing hearts.

The team analyzed tissue from 36 individuals, examining how genes turn on and off across 750,000 heart cells. They identified twelve major cell types, finding that failing hearts possess fewer muscle cells and higher counts of immune cells and structural fibroblasts. These shifts highlight how genetic changes in noncoding DNA contribute to disease progression.

By observing the transitions between healthy and diseased states in muscle cells, the researchers identified new potential sites for medical intervention. This map allows scientists to pinpoint which genes are causal rather than circumstantial, addressing a significant hurdle in current cardiovascular medicine. The data integrates genome-wide association studies to show how specific DNA interactions influence gene expression.

This work serves as a resource for the broader scientific community to develop new therapies. The study identifies specific regulatory regions in muscle cells as primary targets for drug development. Moving forward, this framework connects patient-donated tissue samples to actionable biological pathways, aiming to bridge the gap between genetic risk and patient care.